Books in Pharmaceutical sciences

421-430 of 465 results in All results

Innovations in Adolescent Substance Abuse Interventions

1st Edition
September 14, 2001
Eric Wagner + 1 more
English
Hardback
9 7 8 - 0 - 0 8 - 0 4 3 5 7 7 - 0
eBook
9 7 8 - 0 - 0 8 - 0 5 0 8 7 7 - 1

Innovations in Adolescent Substance Abuse Interventions focuses on developmentally appropriate approaches to the assessment, prevention, or treatment of substance use problems among adolescents. Organized into 16 chapters, this book begins with an assessment of adolescent substance use; theory, methods, and effectiveness of a drug abuse prevention approach; and problem behavior prevention programming for schools and community groups. Some chapters follow on the community-, family- and school-based interventions for adolescents with substance use problems. Other chapters explain psychopharmacological therapy; the assertive aftercare protocol for adolescent substance abusers; and twelve-step-based interventions for adolescents.

Side Effects of Drugs Annual

1st Edition
Volume 24
August 23, 2001
Jeffrey K. Aronson
English
Hardback
9 7 8 - 0 - 4 4 4 - 5 0 5 1 2 - 5

The Side Effects of Drugs Annual is designed to provide a critical and up-to-date account of new information related to adverse drug reactions and interactions from the clinician's point of view. Under the supervision of the series editors, an international team of expert authors have gathered together the latest information on adverse drug effects from the international literature. In addition to describing new reports of adverse drug effects, the authors have subjected those reports to critical analysis, setting them into context in terms of clinical relevance and importance, and cross-referring to previous reports where necessary. New adverse effects are reported and evaluated and previously reported adverse effects are re-evaluated in the light of the most recent information. A special feature is the reviews, in which selected adverse effects are discussed in depth. The use of the book is enhanced by two separate indexes, allowing the reader to enter the text by drug name, adverse effect name, or drug interaction. The current Annual is the first update of the standard encyclopaedic work in this field, http://www.elsevier.nl/locate/isbn/0444500936Meyler's Side Effects of Drugs, Fourteenth Edition, which was published in December 2000.

Handbook of Modern Pharmaceutical Analysis

1st Edition
Volume 3
July 26, 2001
Satinder Ahuja + 1 more
English
Hardback
9 7 8 - 0 - 1 2 - 0 4 5 5 5 5 - 3
eBook
9 7 8 - 0 - 0 8 - 0 4 8 8 9 2 - 9

This book describes the role modern pharmaceutical analysis plays in the development of new drugs. Detailed information is provided as to how the quality of drug products is assured from the point of discovery until the patient uses the drug. Coverage includes state-of-the-art topics such as analytics for combinatorial chemistry and high-throughput screening, formulation development, stability studies, international regulatory aspects and documentation, and future technologies that are likely to impact the field. Emphasis is placed on current, easy-to-follow methods that readers can apply in their laboratories.No book has effectively replaced the very popular text, Pharmaceutical Analysis, that was edited in the 1960s by Tak Higuchi. This book will fill that gap with an up-to-date treatment that is both handy and authoritative.

Analytical Profiles of Drug Substances and Excipients

1st Edition
Volume 27
March 12, 2001
Harry G. Brittain
English
Hardback
9 7 8 - 0 - 1 2 - 2 6 0 8 2 7 - 8
eBook
9 7 8 - 0 - 0 8 - 0 8 6 1 2 2 - 7

Although the official compendia define a drug substance as to identity, purity, strength, and quality, they normally do not provide other physical or chemical data, nor do they list methods of synthesis or pathways of physical or biological degradation and metabolism. Such information is scattered throughout the scientific literature and the files of pharmaceutical laboratories.Edited by the Associate Director of Analytical Research and Development for the American Association of Pharmaceutical Scientists, Analytical Profiles of Drug Substances and Excipients brings this information together in one source. The scope of the series has recently been expanded to include profiles of excipient materials.

Controlled Release Veterinary Drug Delivery

1st Edition
July 20, 2000
Michael J. Rathbone + 1 more
English
Hardback
9 7 8 - 0 - 4 4 4 - 8 2 9 9 2 - 4
eBook
9 7 8 - 0 - 0 8 - 0 5 2 9 9 7 - 4

Many controlled release veterinary drug delivery systems (CRVDDS) are presently in use, and recently there has been a host of new CRVDDS within veterinary medicine. The challenges of this area of drug delivery arise from the unique anatomy and physiology of the target animal, the cost constraints associated with the value of the animal being treated and the extended periods of time that delivery must be sustained for (often measured in months).The purpose of this book is to introduce the reader to the unique opportunities and challenges of the field of CRVDDS and to explain and discuss the basic controlled release principles underlying the development of CRVDDS. Its aim is to provide an overview of many of the areas where CRVVDS have application, and to highlight the opportunities and prospects for controlled release technology in the veterinary field.Controlled Release Veterinary Drug Delivery comprises chapters that provide workers in the field (and those interested in this area) with information on the design, development and assessment of a variety of CRVDDS. The book contains chapters that describe the relevant animal physiological and anatomical considerations alongside descriptions of current and emerging controlled release delivery systems for a variety of routes for drug delivery, and present overviews on the physical and chemical assessment of veterinary controlled release delivery systems.The veterinary area is abound with opportunities for the development of controlled release drug delivery technologies. It is an area of medicine that is open to the acceptance of novel drug delivery devices, and which readily encompasses the use of novel routes of administration. It is an area of many unmet needs, most of which offer opportunities and unique challenges for the innovative formulation scientist to provide solutions. This book will provide an insight into the biological, clinical and pharmaceutical challenges that face the formulation scientist in this interesting and diverse area of research.

Receptor Chemistry Towards the Third Millennium

1st Edition
Volume 31
May 31, 2000
M. Gianella + 3 more
English
eBook
9 7 8 - 0 - 0 8 - 0 5 4 0 4 0 - 5

Receptor Chemistry Towards the Third Millennium is the result of papers presented at the 12th Camerino-Noordwijkerhout Symposium, held in Camerino, Italy in September 1999. Although much is known about the way ligands interact with receptors, which have now been isolated, characterized and cloned, many aspects still remain to be explored. In particular, differentiation into distinct subpopulations and the multiplicity of transduction processes offer more specific targets in the search for new drugs.This book will be of interest to medicinal chemists, pharmacologists, biochemists and neurologists and will also be a valuable source of reference for medical students and postgraduate students in related fields.

Handbook of Non-Invasive Drug Delivery Systems

1st Edition
April 1, 2000
Vitthal S. Kulkarni
English
Hardback
9 7 8 - 0 - 8 1 5 5 - 2 0 2 5 - 2
eBook
9 7 8 - 0 - 8 1 5 5 - 2 0 2 6 - 9

With the improvements in formulation science and certain transdermal delivery technologies, the non-invasive mode of drug delivery is now ready to compete with traditional methods of oral and injectible routes of drug delivery. The Handbook of Non-Invasive Drug Delivery Systems encompasses the broad field of non-invasive drug delivery systems that include drug delivery via topical, transdermal-passive, transdermal-active (device- aided enhanced penetration), trans-mucosal membrane, trans-ocular membrane as well as delivery via alveolar membrane from inhaled medication. Patient compliance has been found to be much higher when administrated by non-invasive routes and therefore they are considered to be a preferred mode of drug delivery. The book includes both science and technological aspects of new drug delivery systems. Its unique focus is that it is on new drug delivery systems that are considered to be "non-invasive". Other unique features include a chapter on Regulatory Aspects of non-invasive systems and one on FDA guidance for topical nano-drug delivery. Two chapters covering market trends and perspectives, as well as providing guidance to those marketing such systems are also included.

Advances in Antiviral Drug Design

1st Edition
Volume 3
November 22, 1999
E. De Clercq
English
Hardback
9 7 8 - 0 - 7 6 2 3 - 0 2 0 1 - 7
eBook
9 7 8 - 0 - 0 8 - 0 5 2 6 0 4 - 1

Volume 3 of Advances in Antiviral Drug Design is keeping up with the recent progress made in the field of antiviral drug research and highlights five specific directions that have opened new avenues for the treatment of virus infections. First, the use of lamivudine (3TC) for the treatment of HIV infections, and its more recent introduction for the treatment of hepatitis B virus (HBV) infections, has heralded the transition of D- to L-nucleosides in the antiviral nucleoside drug design, and it is likely that the future will provide more nucleosides of the L-configuration, such as (-)FFC (emtricitabine) and L-FMAU, as will be described by J.-C.G. Graciet and R.F. Shinazi. Second, the acyclic purine nucleoside phosphonates, i.e. PMEA (adefovir and PMPA (tenofovir), offer great potential as both anti-HIV and anti-HBV agents, and both compounds have been the subject of advanced clinical trials in their oral produrg form (adefovir dipivoxil and tenofovir disoproxyl), as mentioned by M.N. Arimilli, J.P. Dougherty, K.C. Cundy, and N. Bischofberger.Third, with the advent of nevirapine, delavirdine, and efavirenz, the NNRTIs have definitely come of age. Emivirine (MKC-442), a derivative of the original HEPT analog that was described in 1989 has now proceeded through pivotal clinical studies, and how this class of compounds evolved is presented in the account of H. Tanaka and his colleagues. Fourth, at the end of 1999, anticipating on the next winter influenza offensive, we should have at end two compounds that specifically inhibit influenza A and B virus infections: zanamivir (by the intranasal route) and oseltamivir (by the oral route). Both compounds have proved effective in the prophylaxis and treatment of influenza A and B virus infections and act through the same mechanism; that is by blocking the viral neuraminidase (or sialidase), a key enzyme that allows the virus to spread from one cell to another (within the respiratory mucosal tract). The design of these sialidase inhibitors will be presented by M. von Itzstein and J.C. Dyason.Fifth, the discovery (in 1996) of the chemokine receptors CXCR4 and CCR5 as essential coreceptors (in addition to the CD4 receptor) for HIV entry into the cells, has boosted an enormous interest in potential antagonists of these receptors. The bicyclams represent the first low-molecular-weight compounds targeted at CXCR4, the coreceptor used by the more pathogenic, T-lymphotropic, HIV strains, to enter the cells. They will be addressed by G.J. Bridger and R.T. Skerlj.The five topics covered in this third volume of Advances in Antiviral Drug Design are in the front line of the present endeavors towards the chemotherapy of virus infections. They pertain to the combat against three of the most important virus infections of current times: HIV, HBV, and influenza virus.

Analytical Profiles of Drug Substances and Excipients

1st Edition
Volume 26
October 5, 1999
Harry G. Brittain
English
Hardback
9 7 8 - 0 - 1 2 - 2 6 0 8 2 6 - 1
eBook
9 7 8 - 0 - 0 8 - 0 8 6 1 2 1 - 0

Although the official compendia define a drug substance as to identity, purity, strength, and quality, they normally do not provide other physical or chemical data, nor do they list methods of synthesis or pathways of physical or biological degradation and metabolism. Such information is scattered throughout the scientific literature and the files of pharmaceutical laboratories. Edited by the Associate Director of Analytical Research and Development for the American Association of Pharmaceutical Scientists, Analytical Profiles of Drug Substances and Excipients brings this information together into one source. The scope of the series has recently been expanded to include profiles of excipient materials.

Advances in Pharmacology

1st Edition
Volume 46
May 5, 1999
J. Thomas August + 3 more
English
Hardback
9 7 8 - 0 - 1 2 - 0 3 2 9 4 7 - 2
eBook
9 7 8 - 0 - 0 8 - 0 5 8 1 3 8 - 5

Each volume of Advances in Pharmacology provides a rich collection of reviews on timely topics. Emphasis is placed on the molecular bases of drug action, both applied and experimental.